Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

Cited by (1,009)

Items 101–200 of 1,009

1. Epithelial Ovarian Cancer: A Review of Current Management
   Amy Guppy, Paul Nathan, Gordon J.S. Rustin · 2005 · Clinical Oncology
2. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis
   Kelly A. Metcalfe, Shelley Gershman, Parviz Ghadirian, Henry T. Lynch, C. Snyder, Nadine Tung, Charmaine Kim‐Sing, Andrea F. Eisen, William David Foulkes, Barry P. Rosen et al. · 2014 · BMJ
3. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
   Emma Nolan, François Vaillant, Daniel G. Branstetter, Bhupinder Pal, Göknur Giner, Lachlan W. Whitehead, Sheau Wen Lok, Gregory Bruce Mann, Kathy Rohrbach, Liya Huang et al. · 2016 · Nature Medicine
4. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis
   Reiko Yoshida · 2020 · Breast Cancer
5. Models of genetic susceptibility to breast cancer
   Antonis C. Antoniou, Douglas F. Easton · 2006 · Oncogene
6. Genetic Predisposition to Breast Cancer: Past, Present, and Future
   Clare Turnbull, Nazneen Rahman · 2008 · Annual Review of Genomics and Human Genetics
7. Genetic epidemiology and public health: hope, hype, and future prospects
   George Davey Smith, Shah B J Ebrahim, Sarah Jane Lewis, Anna Hansell, Lyle John Palmer, Paul Robert Burton · 2005 · The Lancet
8. Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer
   Grant, Robert C., Selander, Iris, Connor, Ashton A., Selvarajah, Shamini, Borgida, Ayelet, Briollais, Laurent, Petersen, Gloria M., Lerner-Ellis, Jordan, Holter, Spring, Gallinger, Steven · 2015 · Gastroenterology
9. Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis
   Patricia G. Moorman, Laura Jean Havrilesky, Jennifer M. Gierisch, Remy R Coeytaux, William J. Lowery, Rachel Peragallo Urrutia, Michaela Ann Dinan, Amanda J McBroom, Vic Hasselblad, Gillian D Sanders et al. · 2013 · Journal of Clinical Oncology
10. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions
    Johnathan M. Lancaster, C. Bethan Powell, Lee-may Chen, Debra L. Richardson · 2014 · Gynecologic Oncology
11. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
    P.J. O'Donovan, David M. Livingston · 2010 · Carcinogenesis
12. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
    Maxwell, Kara N., Wubbenhorst, Bradley, Wenz, Brandon M., De Sloover, Daniel, Pluta, John, Emery, Lyndsey, Barrett, Amanda, Kraya, Adam A., Anastopoulos, Ioannis N., Yu, Shun et al. · 2017 · Nature Communications
13. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts
    Rebecca Kingdom, Caroline Fiona Wright · 2022 · Frontiers in Genetics
14. Racial disparities in BRCA testing and cancer risk management across a population‐based sample of young breast cancer survivors
    Deborah L. Cragun, Anne E. Weidner, Courtney C Lewis, Devon E. Bonner, Jongphil Kim, Susan Thomas Vadaparampil, Tuya Pal · 2017 · Cancer
15. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
    T.C. van Sprundel, Marjanka K. Schmidt, Matti A. Rookus, Richard M. Brohet, Christie J. van Asperen, Emiel J. Th. Rutgers, Laura J. van’t Veer, Rob A.�E.�M. Tollenaar · 2005 · British Journal of Cancer
16. Founder mutations in BRCA1 and BRCA2 genes
    Rita Ferla, Valentina Calò, Sandra Cascio, Gaetana Rinaldi, Giuseppe Badalamenti, Ignazio Ugo Carreca, Eva Surmacz, Giuseppe Colucci, Viviana Bazan, Antonio Dello Russo · 2007 · Annals of Oncology
17. Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Antonis C. Antoniou, Amanda B. Spurdle, Olga M. Sinilnikova, Sue C. Healey, Karen A. Pooley, Rita Katharina Schmutzler, Beatrix Versmold, Christoph Engel, Alfons Meindl, Norbert Arnold et al. · 2008 · The American Journal of Human Genetics
18. Ovarian Cancer Prevention and Screening
    Usha Menon, Chloe Karpinskyj, Aleksandra Gentry‐Maharaj · 2018 · Obstetrics and Gynecology
19. Long-Term Psychological Impact of Carrying a BRCA1/2 Mutation and Prophylactic Surgery: A 5-Year Follow-Up Study
    van Oostrom, Iris, Meijers-Heijboer, Hanne, Lodder, Litanja N., Duivenvoorden, Hugo J., van Gool, Arthur R., Seynaeve, Caroline, van der Meer, Conny A., Klijn, Jan G.M., van Geel, Bert N., Burger, Curt W. et al. · 2003 · Journal of Clinical Oncology
20. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer
    Sarah J. Lord, Wanlu Lei, Paul Craft, Jennifer N. Cawson, Ian T. Morris, Silke Walleser, Alison D Griffiths, S. Parker, Nehmat Houssami · 2007 · European Journal of Cancer
21. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis
    Simona Iodice, Monica Barile, Nicole Rotmensz, Irène Feroce, Bernardo Bonanni, Paolo Radice, Loris Bernard, Patrick Maisonneuve, Sara Gandini · 2010 · European Journal of Cancer
22. Variation of Breast Cancer Risk Among BRCA1/2 Carriers
    Colin B. Begg, Robert W. Haile, Åke Borg, Kathleen E. Malone, PATRICK J. CONCANNON, Duncan C. Thomas, Bryan M. Langholz, Leslie Bernstein, Jørgen H. Olsen, Charles F. Lynch et al. · 2008 · JAMA
23. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance
    Ielizaveta Gorodetska, Iryna A. Kozeretska, Anna Dubrovska · 2019 · Journal of Cancer
24. Management of Male Breast Cancer: ASCO Guideline
    Michael J. Hassett, Mark R. Somerfield, Elisha Baker, Fátima Cardoso, Kari Joanne Kansal, Dylan C. Kwait, Jennifer Kay Plichta, Charite Nicolette Ricker, Anna Roshal, Kathryn J. Ruddy et al. · 2020 · Journal of Clinical Oncology
25. Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application
    Andrew N. Freedman, Daniela Seminara, Mitchell H. Gail, Patricia A. Hartge, Graham A. Colditz, Rachel R. Ballard-Barbash, Ruth M. Pfeiffer · 2005 · JNCI Journal of the National Cancer Institute
26. PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells
    Annabel Quinet, Stephanie Tirman, Jessica Jackson, Saša Šviković, Delphine Sangotokun Lemacon, Denisse Carvajal-Maldonado, Daniel González‐Acosta, Alexandre Teixeira Vessoni, Emily Cybulla, Matthew D. Wood et al. · 2019 · Molecular Cell
27. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer
    Allison W. Kurian, Yun Li, Ann S. Hamilton, Kevin C. Ward, Sarah T. Hawley, Monica Morrow, Marshall Chandler McLeod, Reshma Jagsi, Steven Jay Katz · 2017 · Journal of Clinical Oncology
28. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes
    L. Castéra, S. Krieger, Antoine Rousselin, Angelina Legros, J. Baumann, Olivia Bruet, Baptiste Brault, Robin Fouillet, N. Goardon, Olivier Letac et al. · 2014 · European Journal of Human Genetics
29. Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging
    Sylvia K. Plevritis, Allison W. Kurian, Bronislava M. Sigal, Bruce Lewis Daniel, Debra M. Ikeda, Frank E. Stockdale, Alan M. Garber · 2006 · JAMA
30. Effect of BRCA germline mutations on breast cancer prognosis
    Zora Baretta, Simone Mocellin M. D, Elena Goldin, Olufunmilayo Ibironke Olopade, Dezheng Huo · 2016 · Medicine
31. An integer linear programming approach for finding deregulated subgraphs in regulatory networks
    Christina Backes, Alexander Rurainski, Gunnar W. Klau, Oliver Josef Müller, Daniel Stöckel, Andreas Gerasch, Jan Küntzer, Daniela Maisel, Nicole Ludwig, Matthias Hein et al. · 2011 · Nucleic Acids Research
32. The Genetic Epidemiology of Breast Cancer Genes
    Deborah J. Thompson, Douglas F. Easton · 2004 · Journal of Mammary Gland Biology and Neoplasia
33. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
    Lynn C. Hartmann, Noralane M. Lindor · 2016 · New England Journal of Medicine
34. Relative frequency and morphology of cancers in STK11 mutation carriers1 ☆
    Wendy Lim, Sylviane Olschwang, Josbert J. Keller, Anne Marie Westerman, Fred H. Menko, Lisa A. Boardman, Rodney John Scott, Jill D. Trimbath, Francis M. Giardiello, Stephen B. Gruber · 2004 · Gastroenterology
35. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers
    Sunil R. Lakhani, Sanjiv Manek, Frederique Madeleine Penault-Llorca, Adrienne Margaret Flanagan, Laurent Arnout, Samantha Merrett, Lesley McGuffog, Dawn Steele, Peter Devilee, Jan G.M. Klijn et al. · 2004 · Clinical Cancer Research
36. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer
    Inês Godet, Daniele M. Gilkes · 2017 · Integrative Cancer Science and Therapeutics
37. Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions☆
    J LANCASTER, C BETHANPOWELL, Noah D. Kauff, Ilana A. Cass, L CHEN, K LU, David Gardner Mutch, Andrew Berchuck, Beth Y. Karlan, Thomas J. Herzog · 2007 · Gynecologic Oncology
38. Management of an Inherited Predisposition to Breast Cancer
    Mark E. Robson, Kenneth Offit · 2007 · New England Journal of Medicine
39. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
    Tommy Nyberg, Debra Frost, Daniel Barrowdale, D. Gareth Evans, Elizabeth Kathryn Bancroft, Julian Adlard, Munaza Ahmed, Julian Barwell, Angela F. Brady, Carole Brewer et al. · 2019 · European Urology
40. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
    John R McLaughlin, Harvey A. Risch, Jan Lubiński, Pål Møller, Parviz Ghadirian, Henry T. Lynch, Beth Y. Karlan, David A. Fishman, Barry P. Rosen, Susan L. Neuhausen et al. · 2006 · The Lancet Oncology
41. The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance
    Nele Loret, Hannelore G Denys, Philippe Tummers, Geert Berx · 2019 · Cancers
42. The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Susan J. Ramus, Simon A. Gayther · 2009 · Molecular Oncology
43. Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers
    Allison W. Kurian, Bronislava M. Sigal, Sylvia K. Plevritis · 2009 · Journal of Clinical Oncology
44. S ociety of G ynecologic O ncology recommendations for the prevention of ovarian cancer
    Joan L. Walker, C. Bethan Powell, Lee-may Chen, Jeanne Carter, Victoria Lin Bae-Jump, Lynn P. Parker, Mark E. Borowsky, Randall K. Gibb · 2015 · Cancer
45. RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies
    Antonis C. Antoniou, Olga M. Sinilnikova, Jacques Simard, Mélanie Léoné, Martine Dumont, Susan L. Neuhausen, Jeffery P. Struewing, Dominique Stoppa‐Lyonnet, Laure Barjhoux, David J. Hughes et al. · 2007 · The American Journal of Human Genetics
46. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial
    Yiwey Shieh, Martin Eklund, Lisa Madlensky, Sarah Dilys Sawyer, Carlie K. Thompson, Allison Stover Fiscalini, Elad Ziv, Laura J. van’t Veer, Laura J. Esserman, Jeffrey A. Tice · 2016 · JNCI Journal of the National Cancer Institute
47. Cancer phenomics: RET and PTEN as illustrative models
    Kevin M. Zbuk, Charis Eng · 2006 · Nature reviews. Cancer
48. Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer
    Joanna B. Madalinska, Judith Hollenstein, Eveline M. A. Bleiker, Marc van Beurden, Heiddis Bjork Valdimarsdottir, Leon F.A.G. Massuger, Katja N. Gaarenstroom, Marian J.E. Mourits, René H.M. Verheijen, E.B.L. van Dorst et al. · 2005 · Journal of Clinical Oncology
49. Applying Synthetic Lethality for the Selective Targeting of Cancer
    Donal P. McLornan, Alan F. List, Ghulam Jeelani Mufti · 2014 · New England Journal of Medicine
50. Breast cancer in adolescents and young adults
    Rebecca H. Johnson, Carey K. Anders, Jennifer Keating Litton, Kathryn J. Ruddy, Archie Bleyer · 2018 · Pediatric Blood & Cancer
51. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
    Xiao Li, Ran You, Xinwei Wang, Congxin Liu, Zicheng Xu, Jin Zhou, Bin Yu, Ting Xu, Hongzhou Cai, Qing Zou · 2016 · Clinical Cancer Research
52. Precision Medicine from a Public Health Perspective
    Ramya Ramaswami, Ronald Bayer, Sandro Galea · 2017 · Annual Review of Public Health
53. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
    Angela Joy George, Daniel Riddell, Sheila Seal, Sabrina Talukdar, Shazia Mahamdallie, Elise Ruark, Victoria Cloke, Ingrid Slade, Zoe Kemp, Martin Eric Gore et al. · 2016 · Scientific Reports
54. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
    Isabella Faraoni, Grazia Graziani · 2018 · Cancers
55. Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)
    Nadine Andrieu, David E. Goldgar, Douglas F. Easton, Matti A. Rookus, Richard M. Brohet, Antonis C. Antoniou, Susan Peock, D. Gareth Evans, Diana Eccles, Fiona Douglas et al. · 2006 · JNCI Journal of the National Cancer Institute
56. BRCA in breast cancer: ESMO Clinical Practice Guidelines
    Judith Balmañà, Orland Dı́ez, Isabel Teresa Rubio, Fátima Cardoso · 2011 · Annals of Oncology
57. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)
    Anouk Pijpe, Nadine Andrieu, DF Easton, Ausrele Kesminiene, Elisabeth Cardis, Catherine Noguès, Marion Gauthier‐Villars, Christine Lasset, Jean‐Pierre Fricker, Susan Peock et al. · 2012 · BMJ
58. Mutational signatures are jointly shaped by DNA damage and repair
    Nadezda V. Volkova, Bettina Meier, Víctor González‐Huici, Simone Bertolini, Santiago González, Harald S. Vöhringer, Federico Abascal, Iñigo Martincorena, Peter J. Campbell, Anton Gartner et al. · 2020 · Nature Communications
59. Rare variants in the ATMgene and risk of breast cancer
    David E. Goldgar, Sue C. Healey, James G. Dowty, Leonard Medeiros Da Silva, Xiaoqing Chen, Amanda B. Spurdle, Mary Beth Terry, Mary Daly, Saundra M Buys, Melissa C. Southey et al. · 2011 · Breast Cancer Research
60. Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk
    Mitchell H. Gail · 2008 · JNCI Journal of the National Cancer Institute
61. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
    Gottfried E. Konecny, Rebecca Sophie Kristeleit · 2016 · British Journal of Cancer
62. PARP inhibitors in ovarian cancer
    Elisena Franzese, Sara Centonze, Anna Diana, Francesca Carlino, Luigi Pio Guerrera, Marilena Di Napoli, Ferdinando De Vita, Sandro Pignata, Fortunato Ciardiello, Michele Orditura · 2018 · Cancer Treatment Reviews
63. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers
    Arindam Paul · 2014 · Frontiers in bioscience
64. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
    Melissa C. Southey, David E Goldgar, Robert Winqvist, Katri Pylkäs, Fergus J. Couch, Marc D. Tischkowitz, William David Foulkes, Joe Dennis, Kyriaki Michailidou, Elizabeth Jansen van Rensburg et al. · 2016 · Journal of Medical Genetics
65. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface
    A J Lee, A P Cunningham, Karoline B. Kuchenbaecker, Nasim Mavaddat, Douglas F. Easton, Antonis C. Antoniou · 2013 · British Journal of Cancer
66. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
    P.M.L.H. Vencken, Mieke Kriege, D. Hoogwerf, S. Beugelink, M.E.L. van der Burg, Maartje J. Hooning, EMJJ Berns, Agnes Jager, Margriet J Collee, Curt W. Burger et al. · 2011 · Annals of Oncology
67. Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample
    Colin B. Begg, Irene Orlow, Amanda Hummer, Bruce Konrad Armstrong, Anne Kricker, Loraine D. Marrett, Robert C. Millikan, Stephen B. Gruber, Hoda Anton‐Culver, Roberto Zanetti et al. · 2005 · JNCI Journal of the National Cancer Institute
68. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study
    Adam N. Rosenthal, Lindsay Sarah Macduff Fraser, Susan Philpott, Ranjit Manchanda, Matthew Burnell, Philip David Badman, Richard J. Hadwin, Ivana Rizzuto, Eromosele Oseiwe Benjamin, Naveena Singh et al. · 2017 · Journal of Clinical Oncology
69. Personalized Medicine in the Era of Genomics
    Wylie Burke, Bruce M. Psaty · 2007 · JAMA
70. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management
    Henry T. Lynch, Murray Joseph Casey, Carrie Snyder, Chhanda Bewtra, Jane F. Lynch, Matthew Butts, Andrew K. Godwin · 2009 · Molecular Oncology
71. Topoisomerase IIα in chromosome instability and personalized cancer therapy
    Tongzhen Chen, Yan Kui Sun, Ping Ji, Scott Kopetz, Wei Zhang · 2014 · Oncogene
72. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
    Melissa Cline, Rachel G. Liao, Michael T. Parsons, Benedict Paten, Faisal Alquaddoomi, Antonis C. Antoniou, Samantha M. Baxter, Larry Brody, Robert Mullan Cook-Deegan, Amy Coffin et al. · 2018 · PLoS Genetics
73. Familial Breast Cancer
    Fiona I. Lalloo, D. Gareth Evans · 2012 · Clinical Genetics
74. BRCA in breast cancer: ESMO Clinical Practice Guidelines
    Judith Balmañà, Orland Dı́ez, Isabel Teresa Rubio, M. Castiglione · 2010 · Annals of Oncology
75. Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer
    Scott W Klarenbach, Nicki Sims-Jones, Gabriela Lewin, Harminder Singh, Guylène Thériault, Marcello A. Tonelli, Marion Doull, Susan Courage, Alejandra Jaramillo Garcia, Brett D. Thombs · 2018 · Canadian Medical Association Journal
76. Label-free detection of DNA hybridization based on hydration-induced tension in nucleic acid films
    Johann Mertens, Celia Rogero, Montserrat Calleja, Daniel Ramos, José Ángel Martín-Gago, Carlos Briones, Javier Tamayo · 2008 · Nature Nanotechnology
77. Linking the Cellular Functions ofBRCAGenes to Cancer Pathogenesis and Treatment
    Ashok R. Venkitaraman · 2008 · Annual Review of Pathology Mechanisms of Disease
78. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
    Priyanka Sharma, Jennifer R. Klemp, Bruce F. Kimler, Jonathan D. Mahnken, Larry J. Geier, Qamar J. Khan, Manana Elia, Carol Sue Connor, Marilee McGinness, Joshua Mammen et al. · 2014 · Breast Cancer Research and Treatment
79. Hereditary Breast and Ovarian Cancer
    Alfons Meindl, Nina Caroline Ditsch, Karin Kast, Kerstin Rhiem, Rita Katharina Schmutzler · 2011 · Deutsches Ärzteblatt international
80. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications
    Allison W. Kurian · 2009 · Current Opinion in Obstetrics & Gynecology
81. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
    Bernadette A. M. Heemskerk‐Gerritsen, Agnes Jager, Linetta B. Koppert, A.I.M. Obdeijn, Margriet J Collee, Hanne E.J. Meijers-Heijboer, Denise J. Jenner, Hester S. A. Oldenburg, Klaartje van Engelen, Jakob de Vries et al. · 2019 · Breast Cancer Research and Treatment
82. Tracing the network connecting brca and fanconi anaemia proteins
    Ashok R. Venkitaraman · 2004 · Nature reviews. Cancer
83. Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer
    Jeffrey N. Weitzel, Veronica I. Lagos, Carey A. Cullinane, Patricia J. Gambol, Julie O. Culver, Kathleen Reilly Blazer, Melanie R. Palomares, Katrina J. Lowstuter, Deborah J. MacDonald · 2007 · JAMA
84. Current Management Strategies for Ovarian Cancer
    Giovanni Damiano Aletti, Mary M. Gallenberg, William A. Cliby, Aminah Jatoi, Lynn C. Hartmann · 2007 · Mayo Clinic Proceedings
85. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
    Allison W. Kurian, Elisha Hughes, Elizabeth A. Handorf, Alexander Gutin, Brian A Allen, Anne‐Renee Hartman, Michael J. Hall · 2017 · JCO Precision Oncology
86. Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers
    Andrea F. Eisen, Jan Lubiński, Jacek Gronwald, Pål Møller, H. T. Lynch, J.G.M. Klijn, Charmaine Kim‐Sing, Susan L. Neuhausen, Lucy Gilbert, Parviz Ghadirian et al. · 2008 · JNCI Journal of the National Cancer Institute
87. Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in<i>BRCA1</i>or<i>BRCA2</i>
    Malone, Kathleen E., Begg, Colin B., Haile, Robert W., Borg, Ake, Concannon, Patrick, Tellhed, Lina, Xue, Shanyan, Teraoka, Sharon, Bernstein, Leslie, Capanu, Marinela et al. · 2010 · Journal of Clinical Oncology
88. Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group
    Nadine Andrieu, Douglas F. Easton, Jenny C. Chang-Claude, Matti A. Rookus, Richard M. Brohet, Elisabeth Cardis, Antonis C. Antoniou, Teresa M. U. Wagner, Jacques Simard, D. Gareth Evans et al. · 2006 · Journal of Clinical Oncology
89. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age
    Dorina M. van der Kolk, Geertruida H. de Bock, Beike K. Leegte, Michael Schaapveld, Marian J.E. Mourits, Jakob de Vries, Annemieke H. van der Hout, Jan C. Oosterwijk · 2010 · Breast Cancer Research and Treatment
90. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
    Pascal Pujol, Massimo C.P. Barberis, Philp Beer, Eitan Friedman, Josep Maria Piulats, Ettore Capoluongo, Jesús García‐Foncillas, Isabelle Laure Ray-Coquard, Frederique Madeleine Penault-Llorca, William David Foulkes et al. · 2021 · European Journal of Cancer
91. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models
    Maenhoudt, Nina, Defraye, Charlotte, Boretto, Matteo, Jan, Ziga, Heremans, Ruben, Boeckx, Bram, Hermans, Florian, Arijs, Ingrid, Cox, Benoit, Van Nieuwenhuysen, Els et al. · 2020 · Stem Cell Reports
92. Breast cancer in young women
    Courtney A. Gabriel, Susan M. Domchek · 2010 · Breast Cancer Research
93. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses
    Jean S. Fleming, Clare R. Beaugié, Izhak Haviv, Georgia Chenevix‐Trench, Olivia L. Tan · 2005 · Molecular and Cellular Endocrinology
94. Breast cancer risk-assessment models
    D. Gareth Evans, Anthony Howell · 2007 · Breast Cancer Research
95. BRCA1 functions as a breast stem cell regulator
    William David Foulkes · 2004 · Journal of Medical Genetics
96. Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial
    Ranjit Manchanda, Kelly Loggenberg, Saskia C. Sanderson, Matthew Burnell, Jane Wardle, Sue Gessler, Lucy E. Side, Nyala Balogun, Rakshit Desai, Ajith Kumar et al. · 2014 · JNCI Journal of the National Cancer Institute
97. 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone from Cigarette Smoke Stimulates Colon Cancer Growth via β-Adrenoceptors
    William Ka Kei Wu, Helen Pui Shan Wong, Shi W. Luo, Kevin Chan, Fung Yu Huang, Marco K. C. Hui, Emily K.Y. Lam, Vivian Yvonne Shin, Yi N. Ye, Ying H. Yang et al. · 2005 · Cancer Research
98. BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
    Adriana J. Rijnsburger, Inge-Marie Obdeijn, Reinoutje Kaas, Madeleine M. A. Tilanus‐Linthorst, Carla Boetes, Claudette E. Loo, Martin N.J.M. Wasser, Elisabeth Bergers, Theo Kok, Sara H. Muller et al. · 2010 · Journal of Clinical Oncology
99. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer
    Roelien I. Olivier, M. A. C. Lubsen-Brandsma, Senno Verhoef, Marc van Beurden · 2005 · Gynecologic Oncology
100. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations
     Kavitha Passaperuma, Ellen Warner, Petrina A. Causer, K A Hill, Sandra J. Messner, Jennifer W. H. Wong, Roberta A. Jong, Frances Catriona Wright, Martin J. Yaffe, Elizabeth A. Ramsay et al. · 2012 · British Journal of Cancer